KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Revenue (2016 - 2026)

TherapeuticsMD filings provide 16 years of Revenue readings, the most recent being $724000.0 for Q1 2026.

  • On a quarterly basis, Revenue rose 84.22% to $724000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $3.4 million, a 82.13% increase, with the full-year FY2025 number at $3.0 million, up 71.61% from a year prior.
  • Revenue hit $724000.0 in Q1 2026 for TherapeuticsMD, down from $893000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $68.6 million in Q4 2022 to a low of $53000.0 in Q3 2023.
  • Median Revenue over the past 5 years was $502000.0 (2023), compared with a mean of $4.5 million.
  • Biggest five-year swings in Revenue: crashed 99.27% in 2023 and later surged 932.08% in 2024.
  • TherapeuticsMD's Revenue stood at $68.6 million in 2022, then crashed by 99.27% to $502000.0 in 2023, then surged by 32.87% to $667000.0 in 2024, then surged by 33.88% to $893000.0 in 2025, then decreased by 18.92% to $724000.0 in 2026.
  • The last three reported values for Revenue were $724000.0 (Q1 2026), $893000.0 (Q4 2025), and $784000.0 (Q3 2025) per Business Quant data.